Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in anda

Zydus Cadila Gets USFDA Nod For Arthritis Drug With 180-Days Exclusivity

Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength

Read More

Caplin Steriles Gets USFDA Nod For Generic Migraine, Cluster Headache Injection

Shares of Caplin Point Laboratories were trading at Rs 690.45 per scrip on BSE, up 0.14 per cent from its previous close.

Read More

Alembic Pharma Gets USFDA Nod For Cancer Treatment Drug

The tablet in combination with gemcitabine is also indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Read More

Alembic Pharmaceuticals Gets USFDA Nod For Anti-Depressant Drug

Quoting IQVIA data, Alembic Pharma said Desipramine Hydrochloride Tablets have an estimated market size of USD 7 million for twelve months ending March 2021.

Read More

Alembic Pharma Gets USFDA Nod For Generic Nitrofurantoin Capsules

Shares of Alembic Pharmaceuticals were trading at Rs 982.40 apiece on BSE, down 0.12 per cent from its previous close.

Read More

Sun Pharma Settles Patent Litigation With Celgene Corporation For Cancer Drug Revlimid

Shares of Sun Pharma were trading 0.19 per cent lower at Rs 669.95 apiece on BSE.

Read More

Alembic Pharma Gets USFDA Nod For Bipolar Depression Drug

Alembic Pharma said Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg have an estimated market size of USD 3.7 billion for the twelve months ending December 2020.

Read More

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

Read More

Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg

Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg

Read More

Cipla Receives Final Approval For Generic Version Of Shire’s Firazyr®

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Read More